Ann: Phase III prophylaxis trial for CS-8958 , page-26

The world market for prophylaxis for the flu is relatively tiny. It should be bigger and in Japan the main market, relenza dominates. One half empty study for a market that will take 10 years plus for BTA row to develop and BTA goes down. Inavir prophylaxis wouldnt even be on the cards for BARDA funding at the moment. Maybe in the future but a long while away. I'm pretty fed up with all this at the moment. Mgmt main function is to increase shareholders wealth. They are currently failing miserably and some of those precious funds should be used to kill the shorters here and give us some hope. What a buy at .92 cents or are BTA waiting till they hit 50 cents to buy in.

Be creative. Spin off anti bacterials into separate company or list rsv and hrv on the NASDAQ. Just do something. I'm beyond placating words.